drugset / Trial / NCT03789890

Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants

NCT03789890 ↗

Phase 1 Completed 14 enrolled Bayer
NaSingle-groupOpen-labelOther

Summary

BAY1902607 is a new type of drug under clinical development for different conditions including the treatment of endometriosis, i.e. a condition where the tissue that usually grows inside the womb grows outside of the womb. Itraconazole (ITZ) is an approved drug often used for the treatment of fungal infections and possibly inhibits the breakdown of BAY1902607. In this clinical study, BAY1902607 is given alone by mouth or in combination with ITZ. Researchers want to learn more how quickly and to what extent the study drug BAY1902607 given by mouth to healthy male participants is absorbed by the human body, reaches the blood stream and is excreted again. In addition they want to find out whether the elimination of the study drug BAY1902607 is influenced by ITZ given at the same time.

Timeline

Start
2019-01-08
Primary completion
2019-03-04
Completion
2019-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject BAY1902607 Unknown — Oral
Subject Itraconazole Small molecule 200 mg Oral

Indications

No indication recorded.